Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leadin
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz ......